title: Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
abstract: Respiratory syncytial virus (RSV) is a major cause of respiratory tract disease in infants, aged adults, and immunosuppressed patients. The only approved medicines for RSV disease are administration of prophylatic antibodies or treatment with a synthetic nucleoside. Both approaches are expensive and the latter is not without risk and of controversial benefit. The present investigation studied whether pharmaceutical or biologic compounds based upon chemokines might be useful in preventing RSV disease. Of interest was RANTES/CCL5, which inhibits infection by HIV strains that use chemokine receptor (CCR)-5 as co-receptor. Herein, we report that prior or simultaneous treatment of HEp-2 cells with recombinant human CCL5 provides dose-dependent inhibition of infection with RSV. Other recombinant chemokines (MIP-1alpha/CCL3, MIP-1beta/CCL4, MCP-2/CCL8, eotaxin/CCL11, MIP-1delta/CCL15, stromal cell derived factor (SDF)-1alpha/CXCL12) were not inhibitory. The data suggested that CCL5 might inhibit infection by blocking fusion (F) protein-epithelial cell interactions. Infections by mutant RSV strains deleted of small hydrophobic and/or attachment proteins and only expressing F protein in the envelope were inhibited by prior treatment with CCL5 or a biologically inactive N-terminally modified met-CCL5. Inhibition was also observed when virus adsorption and treatment with CCL5 were performed at 4 degrees C. Flow cytometry further revealed that epithelial cells were positive for CCR3, but not CCR1 or CCR5. Thus, novel mimetics of CCL5 may be useful prophylatic agents to prevent respiratory tract disease caused by RSV.
authors.affiliation: Department of Immunology Research, Wyeth Vaccines Research, Pearl River, New York 10965, USA.
authors.forename: Matthew B
authors.initials: MB
authors.lastname: Elliott
authors.forename: Paul W
authors.initials: PW
authors.lastname: Tebbey
authors.forename: Karin S
authors.initials: KS
authors.lastname: Pryharski
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Scheuer
authors.forename: Todd S
authors.initials: TS
authors.lastname: Laughlin
authors.forename: Gerald E
authors.initials: GE
authors.lastname: Hancock
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D054413:Chemokine CCL11; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D054412:Chemokine CCL8; D054377:Chemokine CXCL12; D019742:Chemokines, CC / Q000378:metabolism / Q000494:pharmacology*; D019743:Chemokines, CXC / Q000494:pharmacology; D004847:Epithelial Cells / Q000821:virology; D006801:Humans; D019402:Macrophage Inflammatory Proteins / Q000494:pharmacology; D018945:Monocyte Chemoattractant Proteins / Q000494:pharmacology; D015846:Monokines / Q000494:pharmacology; D054389:Receptors, CCR1; D054397:Receptors, CCR3; D019713:Receptors, CCR5 / Q000032:analysis; D019707:Receptors, Chemokine / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D014760:Viral Fusion Proteins / Q000502:physiology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; C515456:CCL11 protein, human; C108814:CCL15 protein, human; C483024:CCL5 protein, human; C515453:CCL8 protein, human; C515300:CCR1 protein, human; C515350:CCR3 protein, human; C515255:CXCL12 protein, human; D054413:Chemokine CCL11; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D054412:Chemokine CCL8; D054377:Chemokine CXCL12; D019742:Chemokines, CC; D019743:Chemokines, CXC; D019402:Macrophage Inflammatory Proteins; D018945:Monocyte Chemoattractant Proteins; D015846:Monokines; D054389:Receptors, CCR1; D054397:Receptors, CCR3; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D014760:Viral Fusion Proteins